Exenatide and rimonabant: New treatments that may be useful in the management of diabetes and obesity

Current Diabetes Reports

Volumn 7, Issue 5, 2007, Pages 369-375

  Green, Jennifer B ^a   Feinglos, Mark N ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CANNABINOID RECEPTOR; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; ENDOCANNABINOID; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LISINOPRIL; METFORMIN; MEVINOLIN; MIDAZOLAM; NICOTINE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PLACEBO; RIMONABANT; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; WARFARIN;

ADD ON THERAPY; ALCOHOLISM; BODY MASS; CLINICAL TRIAL; CONTINUOUS INFUSION; DEPRESSION; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME DEGRADATION; EVENING DOSAGE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LOW CALORY DIET; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRESCRIPTION; REVIEW; SIDE EFFECT; SMOKING CESSATION; STOMACH PARESIS; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; PEPTIDES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; VENOMS;

EID: 36749050813     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0060-0     Document Type: Review

References (46)

1. Turner R: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998, 352:837-853.
2. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
3. Curioni CC, Lourenco PM: Long-term weight loss after diet and exercise-a systematic review. Int J Obes 2005, 29:1168-1174.
4. Nauck MA, Homberger E, Siegel EG, et al.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492-498.
5. Mikhail N: Exenatide: a novel approach for treatment of type 2 diabetes. South Med J 2006, 99:1271-1280.
6. Lebovitz H: Diabetes: assessing the pipeline. Atheroscler Suppl 2005, 7:43-49.
7. Holst JJ: Glucagon-like peptide-1: from extract to agent. Diabetologia 2005, 49:253-260.
8. •• Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128:135-148.
9. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
10. Zander M, Madsbad S, Madsen JL, et al.: Effect of 6-week course of glucagons-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
11. Dunning BE, Foley JE, Ahren B: Alpha cell function in health and disease: influence of glucagons-like peptide-1. Diabetologia 2005, 48:1700-1713.
12. Kendall DM, Kim D, Maggs D: Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006, 8:385-396.
13. Hinnen D, Nielsen LL, Waninger A, et al.: Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006, 19:612-620.
14. Keating GM: Exenatide. Drugs 2005, 65:1681-1692.
15. Schnabel CA, Wintle M, Kolterman O: Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag 2006, 2:69-77.
16. Fehse F, Trautmann M, Hoist JJ, et al.: Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:5991-5997.
17. Buse JB, Fineman MS, Henry RR: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
18. DeFronzo RA, Kim DD, Rather RE: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
19. Kendall DM, Kim DD, Riddle MC: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonyl-urea. Diabetes Care 2005, 28:1083-1091.
20. Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
21. Ratner RE, Maggs D, Nielsen LL, et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
22. Riddle MC, Henry RR, Poon TH, et al.: Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006, 22:483-491.
23. Buse JB, Klonoff DC, Nielsen LL, et al.: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139-153.
24. Zinman B, Hoogwerf BJ, Duran Garcia S, et al.: The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007, 146:477-485.
25. Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005, 143:559-569.
26. Nauck MA, Duran S, Kim D, et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with a sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
27. Yoo BK: Exenatide: a new option for the treatment of type 2 diabetes. Ann Pharmacother 2006, 40:1777-1784.
28. Amylin Pharmaceuticals: Exenatide prescribing information. http://www.BYETTA.com/index.jsp. Accessed May 14, 2007.
29. Tushuizen ME, Bunck ME, Pouwels MC, et al.: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006, 26:1015-1017.
30. Kim D, MacConnell L, Zhuang D, et al.: Safety and efficacy of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes (abstract 487-P). Diabetes 2006, 55:116.
31. Despres JP, Lemieux I, Almeras N: Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes 2006, 30: S44-S52.
32. Carai MAM, Colombo G, Maccioni P, et al.: Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006, 12:91-99.
33. Woods SC: The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med 2007, 120: S9-S17.
34. Kyrou I, Valsamakis G, Tsigos C: The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci 2006, 1083:270-305.
35. Woods SC: Role of the endoeannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med 2007, 120:S19-S25.
36. Engeli S, Bohnke J, Feldpausch M, et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
37. Van Gaal LF, Rissanan AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
38. Despres JP, Golay A, Sjostrom L, et al.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
39. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006, 295:761-775.
40. Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
41. Curioni C, Andre C: Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006, (4):CD006162.
42. Boyd ST, Fremming BA: Rimonabant-a selective CB1 antagonist. Ann Pharmacother 2005, 39:684-690.
43. Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
44. Patel PN, Pathak R: Rimonabant: a novel selective cannabinoid-1 receptor antagonist for the treatment of obesity. Am J Health Syst Pharm 2007, 64:481-489.
45. Gadde KM, Allison DB: Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006, 114:974-984.
46. Le Foil B, Goldberg SR: Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005, 312:875-883.